SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+13.07%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$624M
AUM Growth
+$624M
(+4.8%)
Cap. Flow
-$42.5M
Cap. Flow
% of AUM
-6.81%
Top 10 Holdings %
Top 10 Hldgs %
62.73%
Holding
38
New
5
Increased
9
Reduced
19
Closed
5
Top Buys
| 1 |
Biogen
BIIB
|
$27.7M |
| 2 |
Viatris
VTRS
|
$22.4M |
| 3 |
Takeda Pharmaceutical
TAK
|
$13.2M |
| 4 |
Bristol-Myers Squibb
BMY
|
$11M |
| 5 |
Gilead Sciences
GILD
|
$9.39M |
Top Sells
| 1 |
Merck
MRK
|
$28.4M |
| 2 |
SHPG
Shire pic
SHPG
|
$21.9M |
| 3 |
CELG
Celgene Corp
CELG
|
$16.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$11.8M |
| 5 |
Abbott
ABT
|
$10.7M |
Sector Composition
| 1 | Healthcare | 98.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $64.8M | 10.39% | 1,358,470 +230,000 | +20% | +$11M |
|
|
2
Abbott
ABT
$231B
| $61M | 9.79% | 763,676 -133,600 | -15% | -$10.7M |
|
3
Boston Scientific
BSX
$156B
| $42.8M | 6.86% | 1,115,174 -193,200 | -15% | -$7.41M |
|
|
4
Gilead Sciences
GILD
$140B
| $37.6M | 6.03% | 578,737 +144,380 | +33% | +$9.39M |
|
5
Baxter International
BAX
$12.7B
| $36.4M | 5.84% | 448,228 -41,400 | -8% | -$3.37M |
|
|
6
Biogen
BIIB
$19.4B
| $35.5M | 5.69% | 150,200 +117,100 | +354% | +$27.7M |
|
7
Revvity
RVTY
$10.5B
| $33.1M | 5.3% | 343,081 -16,000 | -4% | -$1.54M |
|
|
NUVA
8
DELISTED
NuVasive, Inc.
NUVA
| $30.6M | 4.91% | 538,625 +64,702 | +14% | +$3.67M |
|
9
Bio-Rad Laboratories Class A
BIO
$8.06B
| $26.7M | 4.28% | 87,397 -9,300 | -10% | -$2.84M |
|
10
Agilent Technologies
A
$35.7B
| $22.5M | 3.61% | 280,351 -34,700 | -11% | -$2.79M |
|
11
Incyte
INCY
$16.5B
| $22.5M | 3.6% | 261,293 -75,151 | -22% | -$6.46M |
|
|
12
Viatris
VTRS
$12.3B
| $22.4M | 3.59% | +790,700 | New | +$22.4M |
|
|
13
Ionis Pharmaceuticals
IONS
$6.79B
| $19M | 3.04% | 233,714 -145,707 | -38% | -$11.8M |
|
14
Qiagen
QGEN
$10.1B
| $16.2M | 2.59% | 396,990 -10,416 | -3% | -$424K |
|
15
CVS Health
CVS
$92.8B
| $16.1M | 2.58% | 298,733 +32,063 | +12% | +$1.73M |
|
16
Perrigo
PRGO
$3.27B
| $14.8M | 2.38% | 308,020 +1,200 | +0.4% | +$57.8K |
|
|
17
Takeda Pharmaceutical
TAK
$47.3B
| $13.2M | 2.12% | +647,451 | New | +$13.2M |
|
18
Elevance Health
ELV
$71.8B
| $11.2M | 1.8% | 39,013 -34,500 | -47% | -$9.9M |
|
|
19
Merck
MRK
$210B
| $9.93M | 1.59% | 119,352 -341,694 | -74% | -$28.4M |
|
|
PDCO
20
DELISTED
Patterson Companies, Inc.
PDCO
| $9.84M | 1.58% | 450,363 -31,900 | -7% | -$697K |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.43M | 1.51% | 379,777 +44,200 | +13% | +$1.1M |
|
|
PTLA
22
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $8.83M | 1.42% | 254,501 -30,200 | -11% | -$1.05M |
|
23
Universal Health Services
UHS
$11.6B
| $8.42M | 1.35% | 62,906 -15,000 | -19% | -$2.01M |
|
24
Cardinal Health
CAH
$35.5B
| $7.83M | 1.26% | 162,635 -43,700 | -21% | -$2.1M |
|
25
PTC Therapeutics
PTCT
$3.92B
| $7.33M | 1.18% | +194,743 | New | +$7.33M |
|